samedan logo
 
 
 
spacer
home > pmps > winter 2001 > developments in the biotechnology and pharmaceutical sectors
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Developments in the biotechnology and pharmaceutical sectors

Perhaps you can begin by giving a brief
overview of your company?

Avecia was formed in July 1999, following completion of a US$2.1 billion (£1.3 billion) buyout of the former Zeneca Specialties business from AstraZeneca. The deal was financed by Cinven and Investcorp - two of Europe's leading financial investment firms.

With sales of £700 million in 2000 and earnings of over £150 million, Avecia is one of Europe's leading and most profitable speciality chemical companies.

Avecia businesses are linked by common scientific and technical capabilities and are focused on delivering service to customers across a wide range of industries including health care, agrochemicals, coatings, graphic arts, leather imaging, mining, plastics, biotechnology, inks and automotive. The company has 4,700 employees and operates in the UK, US, Europe and the Far East.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Patricia Lobo, Editor of PMPS
John Blackie is currently the General Manager of Manufacturing for Pharmaceuticals and Biotechnology at Avecia. He is based in Scotland with accountability for manufacturing in Grangemouth in Scotland, Huddersfield in West Yorkshire and Billingham Teeside in north-east England. John graduated in chemical engineering from the University of Edinburgh.

After a few years in plant design and development, he entered manufacturing management. John has held a
variety of posts in site and operations management over 20 years within the ICI, Zeneca and most recently, Avecia groups. He has been a Senior Manager responsible for manufacturing in the UK for nine years and has spent two and a half years running Syngenta's (formerly Zeneca's) Belgian operations.


spacer
Patricia Lobo
spacer
spacer
spacer
John Blackie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New laboratory and regulatory services for biotech customers

USA/Germany, September 21, 2020. Gerresheimer adds essential laboratory and regulatory services to its broad portfolio of products, solutions and services for biotech companies. Specialized laboratory technicians and an experienced team of further specialists offer these services in the two innovation and technology centers in Bünde (Germany) and Vineland (New Jersey/USA). Gx Biological Solutions offers full service for biotech companies regarding product development of primary packaging and drug delivery solutions, material and functional testing as well as comprehensive regulatory support. The partnership with Gerresheimer shortens the time to market for pharmaceutical companies, minimizes risks and saves resources.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement